Get the Stockscreener App
16.18
1.46%
-0.24
After Hours:
15.95
-0.23
-1.42%
Rigel Pharmaceuticals stock is traded at $16.18, with a volume of 1.45M.
It is down -1.46% in the last 24 hours and up +20.39% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$16.42
Open:
$16.3
24h Volume:
1.45M
Relative Volume:
8.35
Market Cap:
$286.36M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-73.55
EPS:
-0.22
Net Cash Flow:
$-20.74M
1W Performance:
+18.45%
1M Performance:
+20.39%
6M Performance:
+9.32%
1Y Performance:
+49.81%
1-Day Range:
$15.51
$16.77
1-Week Range:
$13.91
$17.18
52-Week Range:
$7.12
$17.30
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges - Investing.com
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com UK
Rhumbline Advisers Has $205,000 Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Update - MarketBeat
High Growth Tech Stocks in the United States to Watch - Simply Wall St
Bank of New York Mellon Corp Sells 464,517 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? - MSN
Armistice Capital LLC Has $13.35 Million Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth - Simply Wall St
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? - Yahoo Finance
Rigel Pharmaceuticals, Inc. Announces Resignation of Brian Kotzin as Member of the Board of Director, Member of the Corporate Governance, Healthcare Compliance Oversight, and Nominating Committee and Chair of the Scientific and Clinical Trial Advisory - Marketscreener.com
Cantor Fitzgerald Reaffirms Neutral Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals announces board resignation By Investing.com - Investing.com Australia
Rigel Pharmaceuticals announces board resignation - Investing.com
Rigel Pharmaceuticals announces board resignation By Investing.com - Investing.com Canada
Rigel Pharmaceuticals announces board resignation By Investing.com - Investing.com South Africa
Dr. Brian Kotzin Resigns from Rigel Pharmaceuticals’ Board - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above Two Hundred Day Moving Average of $11.31 - MarketBeat
Rigel Pharma To Present At Cantor Global Healthcare Conference; Webcast At 9:10 AM ET - Nasdaq
(RIGL) On The My Stocks Page - Stock Traders Daily
Rigel to Present at the 2024 Cantor Global Healthcare Conference - StockTitan
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Passes Above 200-Day Moving Average of $11.37 - Defense World
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above 200 Day Moving Average of $11.37 - MarketBeat
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial - Clinical Trials Arena
Pharma Co. Enrolls First Patient in Trial - Streetwise Reports
US-based Rigel inks $162.5 M oncology deal with Kissei for Japan, Korea and Taiwan markets - BSA bureau
Rigel Pharmaceuticals: First patient enrolled in Phase 1b/2 REZLIDHIA trial - TipRanks
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML - PR Newswire
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML - StockTitan
Rigel shares hold buy as analyst reiterates price target on Japan deal - Investing.com Australia
Rigel Pharmaceuticals seals deal with Kissei for olutasidenib By Investing.com - Investing.com Australia
Rigel Pharmaceuticals’ (RIGL) Buy Rating Reaffirmed at HC Wainwright - Defense World
Rigel Pharmaceuticals seals deal with Kissei for olutasidenib - Investing.com
Rigel inks deal to expand REZLIDHIA in Asian markets - Investing.com
Rigel Pharmaceuticals seals deal with Kissei for olutasidenib - Investing.com India
Rigel shares hold buy as analyst reiterates price target on Japan deal - Investing.com
Rigel expands deal with Kissei to include Rezlidhia - The Pharma Letter
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Reiterated by HC Wainwright - MarketBeat
Rigel inks deal to expand REZLIDHIA in Asian markets By Investing.com - Investing.com Canada
Rigel shares hold buy as analyst reiterates price target on Japan deal - Investing.com Canada
Rigel shares hold buy as analyst reiterates price target on Japan deal - Investing.com India
Rigel shares hold buy as analyst reiterates price target on Japan deal - Investing.com UK
Rigel Pharmaceuticals enters license and supply agreement with Kissei Pharma - TipRanks
Rigel Pharmaceuticals, Inc. Expands Relationship with Kissei Pharmaceutical Co., Ltd. to Include REZLIDHIA (Olutasidenib) in Japan, Republic of Korea and Taiwan - Marketscreener.com
Rigel inks deal to expand REZLIDHIA in Asian markets By Investing.com - Investing.com UK
Kissei Pharmaceutical Co., Ltd. agreed to acquire exclusive development and commercialization rights acute myeloid leukemia drug from Rigel Pharmaceuticals, Inc.. - Marketscreener.com
Rigel Pharmaceuticals (NASDAQ:RIGL) adds US$26m to market cap in the past 7 days, though investors from three years ago are still down 67% - Simply Wall St
Rigel to Participate in Upcoming September Investor Conferences - The Malaysian Reserve
Trading (RIGL) With Integrated Risk Controls - Stock Traders Daily
With 45% stake, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) seems to have captured institutional investors' interest - Yahoo Finance
Rigel to Participate in Upcoming September Investor Conferences - Marketscreener.com
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):